Immunological Basis for Mepolizumab Activity in COPD
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
The current literature suggests that the mode of action of mepolizumab is to bind with
Interleukin (IL)-5 and block the interaction of IL-5 with the IL-5Ra receptor on eosinophils.
This removal of IL-5 may not explain all of the effects of mepolizumab. The investigators
propose a set of studies to systematically examine the spectrum of effects of this drug on
the immune system.